Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) was the recipient of a significant increase in short interest in May. As of May 15th, there was short interest totalling 65,600 shares, an increase of 64.0% from the April 30th total of 40,000 shares. Approximately 0.0% of the company's stock are sold short. Based on an average trading volume of 256,900 shares, the days-to-cover ratio is currently 0.3 days.
Chugai Pharmaceutical Stock Up 4.1%
CHGCY stock traded up $1.08 during trading hours on Monday, hitting $27.16. The company's stock had a trading volume of 65,446 shares, compared to its average volume of 193,407. The company has a market capitalization of $89.38 billion, a PE ratio of 35.27 and a beta of 0.76. The stock has a 50 day moving average price of $25.87 and a two-hundred day moving average price of $23.64. Chugai Pharmaceutical has a 12 month low of $14.78 and a 12 month high of $31.26.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.19 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. The company had revenue of $1.89 billion for the quarter. Sell-side analysts expect that Chugai Pharmaceutical will post 0.74 earnings per share for the current year.
About Chugai Pharmaceutical
(
Get Free Report)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
Further Reading
Before you consider Chugai Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.
While Chugai Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
